Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy

被引：31

作者：

Devillier, Raynier ^{[1
,2
,3
]}

Chretien, Anne-Sophie ^{[1
,2
]}

Pagliardini, Thomas ^{[1
,2
,3
]}

Salem, Nassim ^{[1
,2
]}

Blaise, Didier ^{[1
,2
,3
]}

Olive, Daniel ^{[1
,2
]}

机构：

[1] Aix Marseille Univ, Paoli Calmettes Inst, INSERM, Immun & Canc Team,CNRS,CRCM, Marseille, France

[2] Paoli Calmettes Inst, Immunomonitoring Platform, Marseille, France

[3] Paoli Calmettes Inst, Hematol Dept, 232 Blvd St Marguerite, Marseille, France

来源：

JOURNAL OF LEUKOCYTE BIOLOGY | 2021年 / 109卷 / 06期

关键词：

NK cells; cancer immunotherapy; checkpoint inhibitors; CAR; NATURAL-KILLER-CELLS; CHIMERIC ANTIGEN RECEPTOR; ACUTE MYELOID-LEUKEMIA; BISPECIFIC ANTI-CD30/CD16A ANTIBODY; PLURIPOTENT STEM-CELLS; ENGINEERED NK-92 CELLS; IFN-GAMMA PRODUCTION; BREAST-CANCER CELLS; IN-VIVO EXPANSION; MULTIPLE-MYELOMA;

D O I：

10.1002/JLB.5MR0920-198RR

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

NK cells are innate immune cells with inherent capabilities in both recognizing and killing cancer cells. NK cell phenotypes and functional alterations are being described with increasing precision among patients harboring various cancer types, emphasizing the critical role that NK cells play in antitumor immune responses. In addition, advances in understanding NK cell biology have improved our knowledge of such alterations, thereby expanding the potential exploitation of NK cells' anticancer capabilities. In this review, we present an overview of (1) the various types of NK cell alterations that may contribute to immune evasion in cancer patients and (2) the various strategies to improve NK cell-based anticancer immunotherapies, including pharmacologic modulation and/or genetic modification.

引用

页码：1071 / 1088

页数：18

共 245 条

[1] Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and insigs [J].

Adams, CM ;

Reitz, J ;

De Brabander, JK ;

Feramisco, JD ;

Li, L ;

Brown, MS ;

Goldstein, JL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (50) :52772-52780

[2] 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells [J].

Altvater, Bianca ;

Landmeier, Silke ;

Pscherer, Sibylle ;

Temme, Jaane ;

Schweer, Katharina ;

Kailayangiri, Sareetha ;

Campana, Dario ;

Juergens, Heribert ;

Pule, Martin ;

Rossig, Claudia .

CLINICAL CANCER RESEARCH, 2009, 15 (15) :4857-4866

[3] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[4] Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape [J].

Anderson, Ana C. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (05) :393-398

[5] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[6] Cytokine therapy reverses NK cell anergy in MHC-deficient tumors [J].

Ardolino, Michele ;

Azimi, Camillia S. ;

Iannello, Alexandre ;

Trevino, Troy N. ;

Horan, Lucas ;

Zhang, Lily ;

Deng, Weiwen ;

Ring, Aaron M. ;

Fischer, Suzanne ;

Garcia, K. Christopher ;

Raulet, David H. .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (11) :4781-4794

[7] Srebp-controlled glucose metabolism is essential for NK cell functional responses [J].

Assmann, Nadine ;

O'Brien, Katie L. ;

Donnelly, Raymond P. ;

Dyck, Lydia ;

Zaiatz-Bittencourt, Vanessa ;

Loftus, Roisin M. ;

Heinrich, Paul ;

Oefner, Peter J. ;

Lynch, Lydia ;

Gardiner, Clair M. ;

Dettmer, Katja ;

Finlay, David K. .

NATURE IMMUNOLOGY, 2017, 18 (11) :1197-+

[8] Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer [J].

Audenet, Francois ;

Farkas, Adam M. ;

Anastos, Harry ;

Galsky, Matthew D. ;

Bhardwaj, Nina ;

Sfakianos, John P. .

WORLD JOURNAL OF UROLOGY, 2018, 36 (11) :1741-1748

[9] Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells [J].

Bachanova, Veronika ;

Sarhan, Dhifaf ;

DeFor, Todd E. ;

Cooley, Sarah ;

Panoskaltsis-Mortari, Angela ;

Blazar, Bruce R. ;

Curtsinger, Julie M. ;

Burns, Linda ;

Weisdorf, Daniel J. ;

Miller, Jeffrey S. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (03) :483-494

[10] Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein [J].

Bachanova, Veronika ;

Cooley, Sarah ;

Defor, Todd E. ;

Verneris, Michael R. ;

Zhang, Bin ;

McKenna, David H. ;

Curtsinger, Julie ;

Panoskaltsis-Mortari, Angela ;

Lewis, Dixie ;

Hippen, Keli ;

McGlave, Philip ;

Weisdorf, Daniel J. ;

Blazar, Bruce R. ;

Miller, Jeffrey S. .

BLOOD, 2014, 123 (25) :3855-3863

← 1 2 3 4 5 6 7 8 9 10 →